Suggestions
Andrea Coravos
CEO/Co-founder at HumanFirst, Research Collaborator at Harvard-MIT Center for Regulatory Science
Andrea Coravos: Co-founder and CEO of HumanFirst, Acquired by ICON plc
Andrea Coravos is the co-founder and CEO of HumanFirst, a company recently acquired by ICON plc, a leading provider of drug development solutions and services.1 HumanFirst is focused on enabling precision measures in clinical research.1
Key Facts about Andrea Coravos::
- Co-founder and CEO of HumanFirst, which was acquired by ICON plc in 20244
- Former Entrepreneur in Residence at the FDA in the Digital Health Unit2
- Previously worked as a software engineer at Instacart and Akili Interactive, a leader in digital medicine2
- Held positions at KKR Capstone and McKinsey, focusing on healthcare, energy, and financial industries2
- Duke University graduate, digital rights advocate, and Taylor Swift fan2
- Occasional writer on her blog and Google Scholar2
- Active on Twitter as @AndreaCoravos5
In a recent article for Intelligent Health, Coravos shared insights on leveraging digital health technologies and wearables to manage chronic conditions, drawing from her Lancet Digital Health review.36
Highlights
Last week, I had the pleasure of being back in SF to attend Angel Island, Village Global's premier gathering for angels and solo GPs. The event was a brilliant mix of peer-led discussions and curated small group meetings, sparking insightful conversations on sourcing and diligence, pricing discipline in the era of AI, portfolio construction, and much more.
While living in Dublin, Ireland continues to captivate me for a bajillion reasons, it was magical to return to the Bay Area and re-connect with fellow angels and solo fund managers. The energy, ambition, and shared knowledge is unmatched in California.
You might have heard the big news through the grapevine: ICON plc (NASDAQ: ICLR) has officially acquired HumanFirst. Big thank you to Mario Aguilar at STAT for his clear writing and thoughtful deep dive on precision measures -- and why this transaction is key to accelerate patient-centered research.
By joining forces, HumanFirst will work alongside Mapi Research Trust, bringing together two of the largest precision measures platforms spanning 3,100+ DHTs and 6,000+ COAs, backed by 14,000+ pieces of evidence -- and we’re just getting started.
Stay tuned for more updates as we embark on this exciting journey together!
